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dysfunction in cfS/Me using a 
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Karl J. Morten2
the mitochondrial energy score (MeS) protocol, developed by the Myhill group, is marketed as a 
diagnostic test for chronic fatigue syndrome/Myalgic Encephalomyelitis (CFS/ME). This study assessed 
the reliability and reproducibility of the test, currently provided by private clinics, to assess its 
potential to be developed as an NHS accredited laboratory test. We replicated the MES protocol using 
neutrophils and peripheral blood mononuclear cells (PBMCs) from CFS/ME patients (10) and healthy 
controls (13). The protocol was then repeated in PBMCs and neutrophils from healthy controls to 
investigate the effect of delayed sample processing time used by the Myhill group. Experiments using 
the established protocol showed no differences between CFS/ME patients and healthy controls in any 
of the components of the MeS (p ≥ 0.059). Delaying blood sample processing by 24 hours (well within 
the 72 hour time frame quoted by the Myhill group) significantly altered many of the parameters used 
to calculate the MES in both neutrophils and PBMCs. The MES test does not have the reliability and 
reproducibility required of a diagnostic test and therefore should not currently be offered as a diagnostic 
test for CFS/ME. The differences observed by the Myhill group may be down to differences in sample 
processing time between cohorts.
Chronic Fatigue Syndrome/Myalgic Encephalomyelitis (CFS/ME) affects 250,000 people in the UK1. With an 
unknown cause and currently no accredited diagnostic tests or widely effective treatment options, focusing on 
physiological symptoms treatment management remains difficult1. The uncertainty around the aetiopathogene-
sis of the disease and lack of known biomarkers means there are currently no accredited diagnostic tests. This is 
problematic not only for diagnosis but when assessing new treatments in clinical trials2. Studies suggest that CFS/
ME may be associated with abnormalities of energy production or mitochondrial function3–6. The Mitochondrial 
Energy Score procedure was developed by Myhill et al. and first published in 20097. Subsequently it has been 
described as a test which should be made available to all CFS/ME patients and used as part of treatment manage-
ment8,9. The test is currently offered by several private clinics who offer treatment based on the results. A pub-
lished audit of results confirming the benefits of treatments or that an improvement energy score correlates with 
patient improvement has yet to be documented. Although not offered by the NHS in the UK, many patients pay 
for the test privately and approach their NHS clinician with the results. The Myhill test aims to correlate neutro-
phil mitochondrial dysfunction, measured as total cellular ATP, to the severity of disease in CFS/ME patients7–9. If 
the Myhill test can be confirmed as a specific and reliable test for mitochondrial dysfunction in CFS/ME it would 
be a great benefit to patients in management of their symptoms and assessing the effectiveness of new clinical 
treatments.
In order to add robustness to our approach, teams in two separate laboratories (Newcastle & Oxford) were 
invited to set up the Myhill protocol independently. The aims of this study were two-fold. Firstly, we set out to 
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follow the Myhill protocol in order to determine if live cells isolated from whole blood can be reliably used to 
assess mitochondrial function and whether this approach has the potential to be developed as an NHS accredited 
laboratory test. Then we went on to explore whether the conditions recommended for transport and storage, and 
the cell type used, could have influenced test outcome.
Results
Participant characteristics. Table 1 shows the number of participants, age and gender for the control and 
CFS/ME groups in this study.
Myhill test. For each of the parameters calculated in this study using the MES protocol results are shown as 
a combination of fresh and frozen cells for the healthy control and CFS/ME cohorts. There were no significant 
differences between fresh and frozen neutrophils or PBMCs for any of the parameters in either healthy controls 
or CFS/MS patients (Supplementary Information). Therefore, the fresh and frozen samples were pooled for the 
experiments described below and shown in Fig. 1.
ATP concentration in the presence of excess magnesium. The first experiment investigated the ATP concentra-
tion in neutrophils and PBMCs in the presence of excess magnesium in CFS/ME patients and healthy controls 
(Fig. 1A,B). Magnesium is required for the intracellular production of ATP. The addition of magnesium to the 
cells eliminates the effect of differing inter-participant magnesium levels. Results showed there to be no difference 
in the concentration of ATP between CFS/ME patients and controls in either neutrophils (p = 0.295) or PBMCs 
(p = 0.059).
ATP concentration in the presence of endogenous magnesium. ATP concentration was investigated in the absence 
of excess magnesium. Magnesium deficiencies have previously been reported in a subset of CFS/ME patients10,11, 
however, this was not shown in all studies investigating magnesium status in CFS/ME12. Magnesium is required 
as a co-factor for the production of ATP, therefore, the measurement of ATP production with only endogenous 
magnesium present in the cells gives a more accurate indication of the ATP actually being produced by the cells 
as opposed to the potential capacity the cells have for ATP production which is shown when excess magnesium 
is added13. Results showed there to be no difference in the concentration of ATP between CFS/ME patients and 
controls in either neutrophils (p = 0.737) or PBMCs (p = 0.947) (Fig. 1C,D).
ATP ratio. A ratio was calculated of ATP with endogenous magnesium to ATP with excess magnesium. This 
shows the proportion of ATP that is available as an energy supply as it is the proportion of ATP complexed with 
magnesium to form MgATP. The ratio was calculated for CFS/ME patients and controls in both neutrophils and 
PBMCs. There was no significant differences in either cell type (p = 0.337 and p = 0.314 respectively), Fig. 1E,F.
ATP to ADP efficiency. The final part of the Acumen protocol studied involved investigating the efficiency of 
the conversion of ADP to ATP. This gives us an estimate of the efficiency at which ADP can be recycled to form 
ATP to provide cellular energy. There were no significant differences between the CFS/ME and control cohorts 
in either the neutrophil (p = 0.054) or PBMCs ADP to ATP efficiency (p = 0.550), Fig. 1G,H. In their protocol 
Acumen refer to this parameter as ‘ADP to ATP efficiency’ however, in their publications on this work7–9 they 
refer to the same parameter as OXPHOS. The label OXPHOS is misleading as the equation relies on the recovery 
rate after the inhibitor has been removed and therefore while OXPHOS is a component of the equation, it is not 
represented by the final numerical value. As long as the % recovery rate is the same between two samples then 
they will have the same value of ADP to ATP efficiency regardless of the % decrease in ATP caused by the addition 
of the OXPHOS inhibitor as illustrated in Fig. 2. This parameter cannot be called OXPHOS, as it is in the papers 
published by the Myhill group.
The % ATP inhibited (the first component of the ADP to ATP efficiency equation) may be used as a more 
accurate representation of OXPHOS as it shows the % of ATP inhibited when OXPHOS is inhibited and therefore 
gives an indication of OXPHOS. However, the value of ATP made by mitochondria after the inhibitor is removed 
(c) will be influenced by substrate flow into the mitochondria. Hence a reduction in (c) may not be a direct effect 
of mitochondrial dysfunction but could be linked to substrate supply into the mitochondria. % ATP inhibited is 
used in Booth et al. and Myhill et al.9, although it is still used alongside the “OXPHOS” parameter in these publi-
cations8,9. The % ATP inhibited can often tell a vastly different story than ADP to ATP efficiency (called OXPHOS 
by Myhill et al.) with neutrophils and PBMCs showing similar values for ADP to ATP efficiency (Fig. 1G,H) but 
very different values for % ATP inhibited by sodium azide (Fig. 3) indicating differing pathways of ATP produc-
tion in the two cell types. Figure 3 shows that a significantly higher % of ATP is inhibited in the PBMCs than in 
neutrophils which suggests that PBMCs in freshly isolated blood rely on OXPHOS for ATP production to a much 
greater extent that neutrophils (p < 0.001). This is in keeping with other previous work14–18 that has shown neu-
trophils to be predominantly glycolytic cells.
Number of 
participants
Age 
(mean ± SD)
Gender 
(M:F)
Healthy control 13 39.1 ± 12.6 4:9
CFS/ME 10 38.7 ± 15.8 2:8
Table 1. Participant characteristics.
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ADP/ATP translocator protein. The part of the protocol investigating ADP/ATP translocator activity was not 
able to be conducted. Key reagents specified in the Acumen protocol for these experiments were no longer avail-
able. Replacements were offered for these products on the manufacturers website, however, as the purpose of this 
study was to investigate the validity of the Acumen protocol in the diagnosis of CFS/ME, it was decided that it 
would be inappropriate to use other reagents not specified by the Acumen protocol.
Figure 1. ATP parameters calculated using the protocol from the Myhill test. ATP concentration in (A) 
neutrophils (p = 0.295) and (B) PBMCs (p = 0.059) of CFS/ME patients and healthy controls in the presence of 
excess magnesium. ATP concentration in the absence of excess magnesium in (C) neutrophils (p = 0.737) and 
(D) PBMCs (p = 0.947). Ratio of ATP concentration in cells with endogenous magnesium to ATP concentration 
in cells with excess magnesium in (E) neutrophils (p = 0.337) and (F) PBMCs (p = 0.314). ADP to ATP 
efficiency in (G) neutrophils (p = 0.054) and (H) PBMCs (p = 0.550). CFS/ME n = 10; control n = 13. Groups 
were compared using Welch’s t-tests.
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Effect of delayed cell isolation. Acumen analyse blood samples that are 24–72 hr post phlebotomy7. We 
had concerns that this time frame was too long for neutrophils which would likely become activated19,20 and most 
of the granulocytes would be lost in that time period which may account for the differences between our results 
(Fig. 1) and the results shown by Myhill et al.7–9. CFS/ME patients and controls could also differ in the degree of 
neutrophil activation over time and as this is an unknown variable could compromise the interpretation of the 
results (i.e. assessing changes in the collection tube rather than differences between the CFS/ME patients and 
controls in vivo). We isolated the cell fractions from fresh blood and blood that had been left for 24 hrs (similar 
to Myhill test samples) in order to determine the effect of delayed cell isolation. We first analysed the samples by 
Flow Cytometry (FACS), a useful tool that separates cells based on their size and internal composition (granular-
ity). The results are shown in Fig. 4.
Figure 4B is the 1 hour PBMC fraction from a Histopaque™ separation and the scatter plot shows no neutro-
phil like cells. Figure 4C is the 1 hour neutrophil layer from a Histopaque™ separation and it shows contamina-
tion with lymphocytes and other cellular debris. Figure 4D–F depict cells that were isolated from blood that had 
spent 24 hrs in heparin at room temperature. The whole white cell fractions in (A) < 1 hr isolation and (D) 24 hr 
isolation show different proportions of neutrophils and lymphocytes in the respective quadrants suggesting that 
the longer processing time has altered cell properties. This could change the properties of the cells in the samples 
isolated at 24 hrs so they no longer reflect cellular function at the time of harvesting. This further complicates 
the interpretation of the data as the assumption is made that both controls and ME/CFS patients cells behave in 
the same way after incubation in a blood tube for 24 hrs. In addition, in the Histopaque™ gradients the 24 hr cell 
populations neutrophil fraction (F) looks quite different to the 1 hr samples (C) with a large drop in neutrophil 
numbers. Overall, Fig. 4 highlights the importance of isolating the cells from fresh blood. If blood has been left 
for an extended period of time cells are lost with further processing using Histopaque™, with additional changes 
in cell morphology possibly due to activation.
Metabolites linked to the TCA and glycolytic cycles are changed significantly with a general increase in mito-
chondrial respiration as glucose levels are reduced21 and significant changes in metabolism (Morten & Mccullagh 
Metabolomics unpublished). Once a blood sample is taken as nutrient levels are not replenished and the millions 
of cells in the sample will deplete nutrients such as glucose over time, which will likely have a significant effect on 
cellular metabolism. We have studied glucose depletion in control blood samples. In Fig. 5 we demonstrated that 
Figure 2. Graphs of equal ADP to ATP efficiency with different profiles. This shows the importance of looking 
at the % drop in ATP after the addition of the inhibitor sodium azide to look at the reliance of cells on OXPHOS.
Figure 3. Percentage of ATP inhibited in neutrophils and PBMCs when OXPHOS inhibitor sodium azide was 
added. Calculated as the amount of ATP after the addition of sodium azide as a percentage of ATP before cells 
are treated. This shows how reliant the cells are on OXPHOS as an energy source. A lower % ATP inhibition 
shows a lower reliance on OXPHOS. N = 23. There were no significant differences between CFS/ME and healthy 
control % ATP inhibition for either cell type (Supplementary Information S3).
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in all blood collection systems glucose levels dropped to below 1 mM over 24 hrs. Even after 2 hrs collection blood 
glucose levels showed a significant drop in glucose levels. It is possible that differences between patients and con-
trols reflect differences generated during prolonged storage and do not reflect differences at the time of sampling.
The results shown in Figs 4 and 5 indicated that these types of experiments should be carried out on cells that 
had been isolated from fresh blood i.e. <1 hr post sampling, which was not the case for samples used by Myhill 
et al.7. It should be noted that all of the samples shown in Fig. 1 were isolated immediately after blood collection.
Figure 4. Cells were analysed using FACS. (A) shows whole blood 1 hr after isolation following RBC lysis. 
Three distinct populations of cells consisting of neutrophils, monocytes and lymphocytes are observed. (B,C) 
were isolated using HistopaqueTM (B) =PBMC (monocytes plus lymphocytes) and (C) =neutrophil fractions 
1 hr after isolation. (D–F) are comparable to (A–C) but 24 hrs after isolation.
Figure 5. Glucose concentration of whole blood from healthy controls over 24 hours. First reading was within 
15 minutes of donation. Control n = 4, groups where compared using Welch’s t-test.
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Effect of delayed cell isolation on Myhill test. Given the differences seen between the properties of cells 
isolated from whole blood at different time points, we repeated the Myhill test using bloods taken from 6 healthy 
controls with one tube of blood processed immediately and the other tube processed 24 hours after blood collec-
tion. The results for each of the parameters for PBMCs and neutrophils are shown in Fig. 6.
The results show a significant reduction in ATP when the cells were isolated 24 hours after collection in 
neutrophils (p < 0.001) and PBMCs (p < 0.008) in both the excess and endogenous magnesium experiments. 
Leaving the blood whole for 24 hours also caused a reduction in the ATP ratio in neutrophils (p = 0.015) but not 
in PBMCs (p = 0.490). The longer sample processing time significantly lowered ADP to ATP efficiency in both 
neutrophils (p = 0.050) and PBMCs (p = 0.005). This implies that the lower ATP seen in CFS/ME cells by the 
Myhill group, may be due to the differences in sample handling between the CFS/ME and control cohorts or a 
difference in controls and CFS/ME cell function over 24–48 hrs. Our results suggest that the fact that the samples 
from CFS/ME patients are sent through the post and processed between 24–72 hours after blood is taken, while 
the control blood are collected in the laboratory on the same day as processing, may be the cause of the differences 
seen between the two cohorts by the Myhill group. An alternative explanation would be the CFS/ME patient and 
control samples behave very differently during prolonged storage.
Neutrophils, as used by Myhill et al., are short lived cells that only last for between 5–90 hours in the 
circulation22. In the context of using neutrophils as an indicator of mitochondrial function it is important to con-
sider that neutrophils in freshly isolated blood sample will be in a non-activated state, which have very different 
energetic demands to those that have been activated by pathogens23.
Discussion
Given the evidence presented here, we advise that the MES test should not be used as a diagnostic test in its cur-
rent form as in this study shows there to be no differences between CFS/ME and control results when the MES 
protocol was followed using fresh blood samples. This is contrary to results from the group who devised the test 
and offer it to patients.
We explored the impact of delayed sample processing on blood glucose concentration in the collection tube as 
a possible explanation for the discrepancies in results between our group and the Myhill group. As expected with 
such high cell numbers the glucose rapidly dropped as the cells utilized the glucose. In addition the neutrophil 
component on FACS analysis in the white cell fraction showed differences in size and granularity between the 
1 hr and 24 hr fractions suggestive of altered properties. Having taken into account a 24 hour delay between blood 
collection and cell isolation, we have shown decreases in ATP parameters in control cells similar to those seen by 
the Myhill group in the CFS/ME patients. We suggest that it is potentially the delay between sample collection 
and cell isolation that is causing the decrease in mitochondrial function previously reported in CFS/ME patients.
While this study used relatively small samples sizes compared with the original study, abnormalities in CFS/
ME patients should be reproducible even in small sample sizes given the current use of this test for diagnostic 
purposes.
The Myhill group have recently altered their protocol to use PBMCs instead of neutrophils, however, this 
research has not been published and we have no information on the control ranges used and whether they were 
developed from blood samples processed over 24 hrs. The CFS/ME PBMC study by Tomas et al. did show the util-
ity of using PBMC using the Seahorse extracellular flux analyser to study energetics3. However, the sudden switch 
to using PBMCs for the MES protocol appears to be as a result of criticism over the use of neutrophils rather than 
being an evidence lead change. There has been no data published from the Myhill group regarding the suitability 
of PBMCs with their previously established protocol, or any publication of results with the new cell type. After 
a diagnosis of CFS/ME is made using the MES test, patients are subsequently sold supplements in order to treat 
their CFS/ME, despite there being no placebo-controlled trial to show their effectiveness. The first peer-reviewed 
publication regarding the MES test from the Myhill group came after they had already been using the test and 
supplement regime with CFS/ME patients despite there being no published evidenced of the effectiveness, relia-
bility, or reproducibility of the test. Additionally, the MES test has not been conducted using other patient groups 
with fatigue as a core symptom, therefore its specificity for CFS/ME has not been confirmed.
If energetic dysfunction is to be used as a marker of CFS/ME its exact role in the condition needs to be better 
understood including studying energetic dysfunction in other fatigue groups. Only when we have clearer under-
standing of the disease process and knowledge of specific factors shown to be different in CFS/ME should we 
consider developing a diagnostic test to aid in treatment strategies and determining outcome in clinical trials.
Clinicians approached by patients with results from the MES test should be advised to interpret the results 
with caution, while patients considering paying for the test should be advised of the lack of supporting scientific 
evidence. The test in its current form does not have the reliability or reproducibility required of a diagnostic test 
and therefore should not be offered by the NHS or private clinics as a diagnostic test for CFS/ME. Other tests of 
energetic dysfunction could be developed using the seahorse extracellular flux assay but more research is required 
as to the meaning of the results in the aetiology of CFS/ME before a test using this approach should be developed.
Methods
A 2016 version of the Myhill protocol was obtained from John McLaren-Howard at Acumen Ltd and followed 
with two exceptions: PBMCs were also collected alongside the neutrophil fraction from the Histopaque™ density 
gradient and both fresh and cryopreserved cells were used. The use of fresh and cryopreserved samples was born 
out of necessity as samples could not be collected in a short enough time frame to conduct the experiments at 
the same time for all CFS/ME samples and controls. Two reagents (Sigma M3260 and P7682) required for the 
Mitochondrial ATP/ADP Translocator assay are longer available therefore this assay was not carried out.
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Ethical approval. Blood samples were obtained from patients fulfilling the Canadian consensus diagnostic 
criteria for CFS/ME and healthy controls after obtaining ethical approval from the National Research Ethics 
Committee North East – Newcastle & North Tyneside (12/NE/0146) (ME/CFS) and County Durham & Tees 
Figure 6. ATP parameters in cells isolated immediately and 24 hours after blood collection. ATP concentration 
in (A) neutrophils and (B) PBMCs of healthy controls in the presence of excess magnesium. ATP concentration 
in the absence of excess magnesium in (C) neutrophils and (D) PBMCs. Ratio of ATP concentration in cells 
with endogenous magnesium to ATP concentration in cells with excess magnesium in (E) neutrophils and (F) 
PBMCs. ADP to ATP efficiency in (G) neutrophils and (H) PBMCs. Control n = 6. Groups were compared 
using paired t-tests.
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Valley (12/NE/0121) (controls)24. All methods were performed in accordance with their relevant guidelines and 
regulations. Blood samples were obtained after obtaining informed written consent from all participants.
Cell Isolation – histopaque™ density gradient. All reagents and equipment were used at room tem-
perature. Blood was collected in lithium heparin tubes. Cells were either isolated from whole blood immediately 
after sample collection, or 24 hours later as indicated in the results section. The samples in the Myhill studies 
had been collected at least 24 hrs (up to 72 hours) prior to processing and sent for analysis via the postal service7. 
Neutrophils and PBMCs were separated using a Histopaque™ density gradient.
The Myhill protocol. ATP assays with and without magnesium. ATP concentrations were determined 
using the ATP Bioluminescent Assay Kit (FLAA) (contains magnesium from Sigma Aldrich (Dorset, UK). Each 
test was run in quadruplicate. For experiments looking at ATP concentration in the presence of endogenous 
magnesium the ATP assay mix FL-MM (Sigma Aldrich) was used to prepare a magnesium free solution the assay 
repeated as before.
ADP to ATP efficiency. The efficiency of the conversion of ADP to ATP was monitored in the presence of excess 
magnesium with and without the complex IV inhibitor sodium azide. ATP concentration was determined as 
described previously. Following treatment with the inhibitor the cell suspension solution was centrifuged to 
remove the inhibitor and the pellet resuspended in SBS (combination of NaCl and KCl phosphate buffered to pH 
7.8). This solution was left at room temperature for 3 minutes before being centrifuged again and the supernatant 
removed. The pellet was resuspended in SBS and ATP concentration determined as described previously giving 
the concentration of ATP generated when the inhibitor had been removed. The aim being to compare the amount 
of ATP generated from cells in the presence of a respiratory chain inhibitor and when it is washed out.
Calculations. A ratio of ATP concentration with endogenous magnesium to ATP concentration in the presence 
of excess magnesium was calculated using the following equation:
=Ratio ATP concentration with endogenous magnesium
ATP concentration in the presence of excess magnesium
The equation used to calculate ADP to ATP efficiency was:
=



−
−



×
c b
a b
ADP to ATP efficiency ( )
( )
100
Where:
a = Initial ATP concentration as determined in ATP concentration experiment
b = ATP concentration in the presence of the ATP inhibitor
c = ATP concentration after removal of the ATP inhibitor
Flow cytometry. Cells were prepared for flow cytometry in one of two ways. The first was using a Histopaque 
gradient to isolate a PBMC fraction and a neutrophil fraction as described earlier and the second method used a 
red blood cell (RBC) lysing solution (Biolegend 420301) using the manufacturers protocol to give the white cell 
fraction. The white cell pellet was re-suspended in 500 µL PBS along with the PBMC and neutrophils from the 
Histopaque isolation, on the BD LSR II flow cytometer. Voltages for the forward scatter (FSC) and side scatter 
(SSC) were adjusted until distinct population of cells were visible on the plot. A low flow rate was used to analyse 
the samples over a 4 minute time period. This procedure was conducted on blood samples prepared at 1 and 
24 hours post collection.
Glucose monitoring of whole blood. Blood was collected from healthy donors in sodium heparin tubes. 
Glucose levels were monitored using Accu-Chek Performa Nano (Roche). First reading was within 15 minutes 
of donation. Vaccutainers where kept at room temperature for the duration of the experiment and periodically 
gently inverted.
Statistics. Assays were performed according to the 2016 Acumen protocol in both neutrophils, as stated in 
the protocol, and PBMCs obtained from 10 CFS/ME patients and 13 control subjects. Statistics were calculated 
using un-paired Welch’s t-tests after testing for normality. For comparisons between cells isolated immediately 
after blood collection and 24 hours later, paired t-tests were used.
Data Availibility
The datasets used in this study are available from the corresponding author on reasonable request.
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